loteprednol etabonate
82034-46-6 cas
Drug Patent Expiry for the week of October 20, 2013
Tradename….LOTEMAX
Applicant………Pharmos
SUSPENSION/DROPS; OPHTHALMIC, o.5%
Generic Name………loteprednol etabonate
Patent No.US 5,540,930
http://www.google.co.in/patents/US5540930
The invention provides novel compositions of matter containing water-insoluble steroid drugs suitable for therapeutic use. The invention provides stable aqueous suspensions of water-insoluble steroid drugs of particle sizes of ≦15 μm which remain in such a state so as to allow for immediate suspension, when desired, even after extended periods of settling.
| Date | Supplement No. | Action | Documents |
|---|---|---|---|
| 1998-03-09 | 000 | Approval |
| Publication number | US5540930 A |
| Publication type | Grant |
| Application number | US 08/142,743 |
| Publication date | 30 Jul 1996 |
| Filing date | 25 Oct 1993 |
| Priority date | 25 Oct 1993 |
| Fee status | Paid |
| Also published as | CA2174550A1, CA2174550C, DE69430635D1, DE69430635T2, EP0730443A1, EP0730443A4, EP0730443B1, US5747061, WO1995011669A1, Less «8 More » |
| Publication number | 08142743, 142743, US 5540930 A, US 5540930A, US-A-5540930, US5540930 A, US5540930A |
| Inventors | Doron I. Friedman, Yaacov J. Guy |
| Original Assignee | Pharmos Corporation |
| Company | |||
|---|---|---|---|
| LOTEMAX NDA (020583) | BAUSCH AND LOMB | LOTEPREDNOL ETABONATE | |
| ALREX NDA (020803) | BAUSCH AND LOMB | LOTEPREDNOL ETABONATE | |
| LOTEMAX NDA (020841) | PHARMOS | LOTEPREDNOL ETABONATE…expired | |
| ZYLET NDA (050804) | BAUSCH AND LOMB | LOTEPREDNOL ETABONATE; TOBRAMYCIN | |
| LOTEMAX NDA (200738) | BAUSCH AND LOMB | LOTEPREDNOL ETABONATE | |
| LOTEMAX NDA (202872) | BAUSCH AND LOMB | LOTEPREDNOL ETABONATE |
Loteprednol (as the ester loteprednol etabonate) is a corticosteroid used in optometry and ophthalmology. Marketed by Bausch and Lomb as Lotemax in the U.S., ocular applications for this drug include the treatment of inflammation of the eye due to allergies (according to the prescription information sheet), as well as chronic forms of keratitis (e.g.: adenoviral and Thygeson’s keratitis), vernal keratoconjunctivitis, pingueculitis, and episcleritis. The drug has little or no effect on intraocular pressure.
Druzgala, P.; Hochhaus, G.; Bodor, N.; J. Steroid Biochem. Mol. Biol. 1991, 38, 149.
http://dx.doi.org/10.1016/0960-0760(91)90120-T
- Steward, R; et al. (November 1998). “Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation”. J Cataract Surg 24: 1480–1489.
- Pavesio, CE; Decory, HH (2008). “Treatment of ocular inflammatory conditions with loteprednol etabonate”. Br J Ophthalmol 92 (4): 455–459. doi:10.1136/bjo.2007.132621. PMID 18245274.
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....

Fajne spojrzenie na rzecz, każdy powinien przeczytać oraz zaznajomić się z przedmiotem.
LikeLike